The United States has authorized a new protective treatment for HIV, according to what the pharmaceutical company “Glyad” has invented it, which may revolutionize the fight against this disease, knowing that the possibility of obtaining treatment is still an existing issue.
This treatment, named “Yazogo” and the author of two annual injections, is a small revolution in the field of drugs that prevent the transmission of HIV, known as drugs “Prevention before exposure”.
A daily dose of these treatments that are concerned with non -injured people should be taken but exposed to the risk of injury.
“Yazogo” provides more effective and less harmful protection, with only two injections annually, and it can be very easy to facilitate the treatment of people at risk, especially in developing countries.
This new treatment also contributes to the elimination of AIDS, according to experts.
“It is a historic day in combating HIV,” said the CEO of the American Biotechnology Company, Daniel Odai, in a statement in which he announced the authorities’ approval of the drug.
According to the laboratory, the new treatment will be currently available in the United States “for adults and adolescents whose weight does not exceed 35 kilograms and needs preventive drugs before exposure or want to benefit from them.”
The issue of cost
Since 2022, Glyad Laboratory Laborators have anti -virus treatment, “Senlinka”, who was invented using the same molecule, Linakapphir. This treatment is provided to people with HIV, and will reduce the proliferation of the virus in the body.
These treatments provide unprecedented effectiveness, and a qualitative shift may cause AIDS, according to experts.
The two clinical experiences conducted by the company for preventive therapy showed a decrease in the risk of HIV transmission by more than 99.9% in adults and adolescents, making it the closest option for the vaccine.
But the hopes raised by these excellent results may dissipate due to the high costs of treatments.
In response to a question from Agence France -Presse, the company explained that the price of “Yazogo” in the United States will reach 28218 dollars annually, “a price that is in line with prevention drugs before exposure currently in the market. However, a spokeswoman for “Glyad” said on Wednesday, “We are working to make Yazogogo within the reach of all those who need or want to take it, and we expect widespread insurance coverage.”
The price of “Sonlinka”, another treatment available in the market, exceeds $ 39,000 annually.
“The first treatment of prevention before exposure is created by” Fif Healthcker “, and the sale of the United States in 2021 was permissible, tens of thousands of dollars annually, and it is taken by injection every two months.
According to recent estimates of a number of researchers published in the magazine “Lancet”, “Linakapafer” can be produced at a price of only 25 and 46 dollars.
“If the price of this medicine, which changes the rules of the game, remains high, nothing will change,” said Winnie Pianima, head of the United Nations Joint HIV/AIDS program.
She called for “cutting the price, increasing production, and ensuring that the world has a chance to eliminate AIDS.”
Last year, Glyad announced agreements with manufacturers to produce and sell low -cost (Generic) drugs in more than a hundred developing countries, and provide many additional doses.
Glyad previously announced agreements with agreements with drug manufacturers to produce and sell low -cost genetics in more than a hundred developing countries, and provide many additional doses.
But these initiatives may be undermined by the Donald Trump administration procedures that reduced the global financing that was supposed to support them.